Novartis trumpets Adakveo hospitalization data by Carly Helfand Sunday, December 8, 2019 With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.
Novartis wins speedy FDA nod for sickle cell drug Adakveo by Angus Liu Saturday, November 16, 2019 Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.
